Answer
Patients receiving immunosuppressive combinations including CellCept have an increased risk of lymphomas and other malignancies, particularly skin cancers, with risk appearing related to the intensity and duration of immunosuppression rather than any specific agent.
Sources for this answer
- Cellcept 500mg powder for concentrate for solution for infusionRoche Products Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 39Document updated
Sources checked